25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Autolus Therapeutics Ltd
Buy, Hold or Sell?

Let's analyze Autolus together

I guess you are interested in Autolus Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Autolus Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Autolus Therapeutics Ltd

I send you an email if I find something interesting about Autolus Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of Autolus (30 sec.)










1.2. What can you expect buying and holding a share of Autolus? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.79
Expected worth in 1 year
$2.91
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$1.11
Return On Investment
44.7%

For what price can you sell your share?

Current Price per Share
$2.49
Expected price per share
$2.15 - $4.12
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Autolus (5 min.)




Live pricePrice per Share (EOD)
$2.49
Intrinsic Value Per Share
$-12.78 - $-15.14
Total Value Per Share
$-10.99 - $-13.35

2.2. Growth of Autolus (5 min.)




Is Autolus growing?

Current yearPrevious yearGrowGrow %
How rich?$476.9m$243.8m$180.7m42.6%

How much money is Autolus making?

Current yearPrevious yearGrowGrow %
Making money-$67.5m-$39.5m-$28m-41.5%
Net Profit Margin-1,217.5%-3,769.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Autolus (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#132 / 944

Most Revenue
#387 / 944

Most Profit
#865 / 944

Most Efficient
#725 / 944
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Autolus?

Welcome investor! Autolus's management wants to use your money to grow the business. In return you get a share of Autolus.

First you should know what it really means to hold a share of Autolus. And how you can make/lose money.

Speculation

The Price per Share of Autolus is $2.49. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Autolus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Autolus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.79. Based on the TTM, the Book Value Change Per Share is $0.28 per quarter. Based on the YOY, the Book Value Change Per Share is $0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Autolus.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.31-12.4%-0.25-10.2%-0.15-6.2%-0.17-6.6%-0.13-5.4%
Usd Book Value Change Per Share-0.19-7.7%0.2811.2%0.020.7%0.041.6%0.062.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.19-7.7%0.2811.2%0.020.7%0.041.6%0.062.4%
Usd Price Per Share3.63-4.98-2.11-5.87-8.92-
Price to Earnings Ratio-2.94--5.13--3.56--9.93--26.56-
Price-to-Total Gains Ratio-18.99--14.32--10.32--41.72--71.66-
Price to Book Ratio2.03-5.52-2.43-6.30-9.62-
Price-to-Total Gains Ratio-18.99--14.32--10.32--41.72--71.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.49
Number of shares401
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.280.04
Usd Total Gains Per Share0.280.04
Gains per Quarter (401 shares)111.6715.62
Gains per Year (401 shares)446.6962.48
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1044743706252
208938840125114
30134013310187176
40178717780250238
50223322250312300
60268026720375362
70312731190437424
80357435660500486
90402040130562548
100446744600625610

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.030.00.00.0%0.030.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%9.019.02.030.0%9.019.02.030.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.030.00.0%0.00.030.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%9.019.02.030.0%9.019.02.030.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Autolus Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1910.278-169%0.018-1151%0.039-591%0.060-420%
Book Value Per Share--1.7921.595+12%0.916+96%1.073+67%0.960+87%
Current Ratio--13.68514.158-3%8.997+52%9.864+39%11.058+24%
Debt To Asset Ratio--0.4240.466-9%0.464-9%0.319+33%0.248+71%
Debt To Equity Ratio--0.7351.067-31%0.895-18%0.572+29%0.421+75%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--1272564860.0001601578365.250-21%676555475.000+88%1727163773.050-26%2903466878.500-56%
Eps---0.308-0.254-18%-0.154-50%-0.166-46%-0.134-57%
Ev To Ebitda Ratio---4.581-10.349+126%-4.833+5%-11.080+142%infnan%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.324-0.193-40%-0.137-58%-0.142-56%-0.129-60%
Free Cash Flow To Equity Per Share---0.3240.333-197%0.072-547%0.073-545%0.067-582%
Gross Profit Margin--1.0001.022-2%1.0000%1.0040%1.0030%
Intrinsic Value_10Y_max---15.137--------
Intrinsic Value_10Y_min---12.778--------
Intrinsic Value_1Y_max---0.724--------
Intrinsic Value_1Y_min---0.710--------
Intrinsic Value_3Y_max---2.779--------
Intrinsic Value_3Y_min---2.641--------
Intrinsic Value_5Y_max---5.563--------
Intrinsic Value_5Y_min---5.112--------
Market Cap662643780.000-46%966022860.0001325952865.000-27%562182725.000+72%1562535323.000-38%2374872728.000-59%
Net Profit Margin----12.1750%-37.6970%-42.4600%-42.0260%
Operating Margin----5.7130%-36.5810%-45.6300%-48.2230%
Operating Ratio---6.969-100%42.307-100%57.998-100%71.525-100%
Pb Ratio1.389-46%2.0255.518-63%2.431-17%6.300-68%9.616-79%
Pe Ratio-2.018+31%-2.942-5.131+74%-3.559+21%-9.932+238%-26.558+803%
Price Per Share2.490-46%3.6304.983-27%2.113+72%5.872-38%8.924-59%
Price To Free Cash Flow Ratio-1.919+31%-2.798-8.471+203%-4.604+65%-12.304+340%-17.819+537%
Price To Total Gains Ratio-13.024+31%-18.987-14.323-25%-10.324-46%-41.724+120%-71.664+277%
Quick Ratio--12.54113.123-4%8.693+44%9.426+33%8.676+45%
Return On Assets---0.099-0.108+9%-0.089-10%-0.109+10%-0.109+10%
Return On Equity---0.172-0.266+55%-0.173+1%-0.180+5%-0.161-6%
Total Gains Per Share---0.1910.278-169%0.018-1151%0.039-591%0.060-420%
Usd Book Value--476965000.000424578250.250+12%243862000.000+96%285499500.050+67%255559800.033+87%
Usd Book Value Change Per Share---0.1910.278-169%0.018-1151%0.039-591%0.060-420%
Usd Book Value Per Share--1.7921.595+12%0.916+96%1.073+67%0.960+87%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--1272564860.0001601578365.250-21%676555475.000+88%1727163773.050-26%2903466878.500-56%
Usd Eps---0.308-0.254-18%-0.154-50%-0.166-46%-0.134-57%
Usd Free Cash Flow---86329000.000-51402499.500-40%-36365500.000-58%-37667999.900-56%-30910833.267-64%
Usd Free Cash Flow Per Share---0.324-0.193-40%-0.137-58%-0.142-56%-0.129-60%
Usd Free Cash Flow To Equity Per Share---0.3240.333-197%0.072-547%0.073-545%0.067-582%
Usd Market Cap662643780.000-46%966022860.0001325952865.000-27%562182725.000+72%1562535323.000-38%2374872728.000-59%
Usd Price Per Share2.490-46%3.6304.983-27%2.113+72%5.872-38%8.924-59%
Usd Profit---82094000.000-67556750.000-18%-39540750.000-52%-43770600.000-47%-35199766.667-57%
Usd Revenue---2966500.000-100%1380750.000-100%1133300.000-100%974716.667-100%
Usd Total Gains Per Share---0.1910.278-169%0.018-1151%0.039-591%0.060-420%
 EOD+3 -5MRQTTM+11 -24YOY+16 -185Y+12 -2310Y+10 -24

3.3 Fundamental Score

Let's check the fundamental score of Autolus Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.018
Price to Book Ratio (EOD)Between0-11.389
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than112.541
Current Ratio (MRQ)Greater than113.685
Debt to Asset Ratio (MRQ)Less than10.424
Debt to Equity Ratio (MRQ)Less than10.735
Return on Equity (MRQ)Greater than0.15-0.172
Return on Assets (MRQ)Greater than0.05-0.099
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Autolus Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.983
Ma 20Greater thanMa 502.977
Ma 50Greater thanMa 1003.589
Ma 100Greater thanMa 2003.776
OpenGreater thanClose2.700
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Autolus Therapeutics Ltd

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Fundamental data was last updated by Penke on 2024-12-05 13:13:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Autolus earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Autolus to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Autolus Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,217.5%+1,217.5%
TTM-1,217.5%YOY-3,769.7%+2,552.2%
TTM-1,217.5%5Y-4,246.0%+3,028.5%
5Y-4,246.0%10Y-4,202.6%-43.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--108.6%+108.6%
TTM-1,217.5%-221.4%-996.1%
YOY-3,769.7%-207.4%-3,562.3%
5Y-4,246.0%-346.2%-3,899.8%
10Y-4,202.6%-470.4%-3,732.2%
4.3.1.2. Return on Assets

Shows how efficient Autolus is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Autolus to the Biotechnology industry mean.
  • -9.9% Return on Assets means that Autolus generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Autolus Therapeutics Ltd:

  • The MRQ is -9.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.9%TTM-10.8%+0.9%
TTM-10.8%YOY-8.9%-1.9%
TTM-10.8%5Y-10.9%+0.1%
5Y-10.9%10Y-10.9%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.9%-11.6%+1.7%
TTM-10.8%-12.0%+1.2%
YOY-8.9%-11.2%+2.3%
5Y-10.9%-12.6%+1.7%
10Y-10.9%-14.1%+3.2%
4.3.1.3. Return on Equity

Shows how efficient Autolus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Autolus to the Biotechnology industry mean.
  • -17.2% Return on Equity means Autolus generated $-0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Autolus Therapeutics Ltd:

  • The MRQ is -17.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -26.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.2%TTM-26.6%+9.4%
TTM-26.6%YOY-17.3%-9.3%
TTM-26.6%5Y-18.0%-8.6%
5Y-18.0%10Y-16.1%-1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.2%-14.5%-2.7%
TTM-26.6%-16.0%-10.6%
YOY-17.3%-14.6%-2.7%
5Y-18.0%-18.5%+0.5%
10Y-16.1%-19.2%+3.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Autolus Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Autolus is operating .

  • Measures how much profit Autolus makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Autolus to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Autolus Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-571.3%+571.3%
TTM-571.3%YOY-3,658.1%+3,086.8%
TTM-571.3%5Y-4,563.0%+3,991.7%
5Y-4,563.0%10Y-4,822.3%+259.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.0%+204.0%
TTM-571.3%-316.8%-254.5%
YOY-3,658.1%-215.6%-3,442.5%
5Y-4,563.0%-376.1%-4,186.9%
10Y-4,822.3%-480.3%-4,342.0%
4.3.2.2. Operating Ratio

Measures how efficient Autolus is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Autolus Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM6.969-6.969
TTM6.969YOY42.307-35.338
TTM6.9695Y57.998-51.030
5Y57.99810Y71.525-13.527
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.284-2.284
TTM6.9693.198+3.771
YOY42.3073.247+39.060
5Y57.9984.651+53.347
10Y71.5256.419+65.106
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Autolus Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Autolus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.69 means the company has $13.69 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Autolus Therapeutics Ltd:

  • The MRQ is 13.685. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.158. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.685TTM14.158-0.473
TTM14.158YOY8.997+5.161
TTM14.1585Y9.864+4.294
5Y9.86410Y11.058-1.194
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.6853.586+10.099
TTM14.1583.869+10.289
YOY8.9974.644+4.353
5Y9.8645.971+3.893
10Y11.0586.240+4.818
4.4.3.2. Quick Ratio

Measures if Autolus is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Autolus to the Biotechnology industry mean.
  • A Quick Ratio of 12.54 means the company can pay off $12.54 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Autolus Therapeutics Ltd:

  • The MRQ is 12.541. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 13.123. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.541TTM13.123-0.582
TTM13.123YOY8.693+4.429
TTM13.1235Y9.426+3.697
5Y9.42610Y8.676+0.750
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.5413.093+9.448
TTM13.1233.392+9.731
YOY8.6934.304+4.389
5Y9.4265.953+3.473
10Y8.6766.435+2.241
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Autolus Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Autolus assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Autolus to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.42 means that Autolus assets are financed with 42.4% credit (debt) and the remaining percentage (100% - 42.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Autolus Therapeutics Ltd:

  • The MRQ is 0.424. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.466. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.424TTM0.466-0.042
TTM0.466YOY0.464+0.001
TTM0.4665Y0.319+0.146
5Y0.31910Y0.248+0.072
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4240.346+0.078
TTM0.4660.347+0.119
YOY0.4640.313+0.151
5Y0.3190.365-0.046
10Y0.2480.383-0.135
4.5.4.2. Debt to Equity Ratio

Measures if Autolus is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Autolus to the Biotechnology industry mean.
  • A Debt to Equity ratio of 73.5% means that company has $0.73 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Autolus Therapeutics Ltd:

  • The MRQ is 0.735. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.067. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ0.735TTM1.067-0.332
TTM1.067YOY0.895+0.172
TTM1.0675Y0.572+0.495
5Y0.57210Y0.421+0.151
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7350.393+0.342
TTM1.0670.432+0.635
YOY0.8950.388+0.507
5Y0.5720.455+0.117
10Y0.4210.498-0.077
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Autolus generates.

  • Above 15 is considered overpriced but always compare Autolus to the Biotechnology industry mean.
  • A PE ratio of -2.94 means the investor is paying $-2.94 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Autolus Therapeutics Ltd:

  • The EOD is -2.018. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.942. Based on the earnings, the company is expensive. -2
  • The TTM is -5.131. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.018MRQ-2.942+0.924
MRQ-2.942TTM-5.131+2.189
TTM-5.131YOY-3.559-1.572
TTM-5.1315Y-9.932+4.801
5Y-9.93210Y-26.558+16.626
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.018-2.180+0.162
MRQ-2.942-2.507-0.435
TTM-5.131-3.153-1.978
YOY-3.559-3.242-0.317
5Y-9.932-5.992-3.940
10Y-26.558-6.690-19.868
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Autolus Therapeutics Ltd:

  • The EOD is -1.919. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.798. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.471. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.919MRQ-2.798+0.879
MRQ-2.798TTM-8.471+5.673
TTM-8.471YOY-4.604-3.866
TTM-8.4715Y-12.304+3.833
5Y-12.30410Y-17.819+5.515
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.919-2.879+0.960
MRQ-2.798-3.276+0.478
TTM-8.471-3.669-4.802
YOY-4.604-4.485-0.119
5Y-12.304-8.015-4.289
10Y-17.819-9.197-8.622
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Autolus is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.03 means the investor is paying $2.03 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Autolus Therapeutics Ltd:

  • The EOD is 1.389. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.025. Based on the equity, the company is underpriced. +1
  • The TTM is 5.518. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD1.389MRQ2.025-0.636
MRQ2.025TTM5.518-3.492
TTM5.518YOY2.431+3.087
TTM5.5185Y6.300-0.782
5Y6.30010Y9.616-3.316
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.3891.964-0.575
MRQ2.0252.056-0.031
TTM5.5182.388+3.130
YOY2.4312.460-0.029
5Y6.3003.697+2.603
10Y9.6164.324+5.292
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Autolus Therapeutics Ltd.

4.8.1. Institutions holding Autolus Therapeutics Ltd

Institutions are holding 76.802% of the shares of Autolus Therapeutics Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Wellington Management Company LLP9.10120.015424220226633039235.3854
2024-09-30Blackstone Inc7.69780.32432048561100
2024-09-30Syncona Portfolio Ltd.6.972283.423818554624-2792205-13.0802
2024-09-30FMR Inc6.67890.003917773873547870644.5598
2024-09-30Deep Track Capital, LP5.73881.75841527217200
2024-09-30venBio Select Advisor LLC4.63910.65351234567800
2024-09-30Polygon Management Ltd3.00618.1911800000000
2024-09-30Armistice Capital, LLC2.58230.39968720006220009.952
2024-09-30Affinity Asset Advisors, LLC1.6912.229245000002000004.6512
2024-06-30BlackRock Inc1.66690.000444361023801829.3735
2024-09-30T. Rowe Price Associates, Inc.1.44350.00163841502-572585-12.9718
2024-09-30Deerfield Management Co1.36740.1974363900000
2024-06-30Great Point Partners LLC1.29332.294434416672275000194.9999
2024-09-30LAURION CAPITAL MANAGEMENT LP1.19850.15723189547-456683-12.5248
2024-09-30Adage Capital Partners Gp LLC1.10850.01892950000-250000-7.8125
2024-09-30Schroder Investment Management Group1.07640.0107286463241259216.8265
2024-09-30StemPoint Capital LP0.98322.84372616602-46130-1.7324
2024-09-30Bank of New York Mellon Corp0.68790.00121830521-701167-27.6956
2024-09-30Morgan Stanley - Brokerage Accounts0.68310.00051817955-3991731-68.7082
2024-09-30Perpetual Ltd0.60090.06291599252-801160-33.3759
Total 60.217102.5875160250964+6087211+3.8%

4.9.2. Funds holding Autolus Therapeutics Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Syncona Ord11.54927.286430734957938812843.979
2024-09-30Vanguard Health Care Inv7.27350.144319356365581535042.9462
2024-06-30FIAM Small Cap Core Composite1.24320.253433083001777500116.1158
2024-09-30FIAM Small Cap Core CIT Cl B1.22760.23943267000-120100-3.5458
2024-09-30Fidelity Advisor Biotechnology I1.13070.5806300914600
2024-08-31Fidelity Small Cap Growth0.96620.1322571371-6727-0.2609
2024-08-31Fidelity Series Small Cap Opps0.94450.1742513475-109200-4.1637
2024-09-30US Small-Cap Growth II Equity Comp0.85240.03872268455-8061-0.3541
2024-09-30T. Rowe Price New Horizons0.85240.03872268455-7148-0.3141
2024-10-31Wellington Global Hlthcr Eq USD G Ac0.69430.275184756367349857.3646
2024-10-31Belfius Equities Cure C Cap0.65510.3115174343717434370
2024-08-31Fidelity Stock Selector Small Cap0.64130.17351706679370002.216
2024-10-31Candriam Eqs L Biotech C USD Cap0.56850.3115151290315129030
2024-10-31AXA Framlington Health Fund - R Income0.52720.7295140307314030730
2024-11-27iShares Biotechnology ETF0.52550.0656139843614210.1017
2024-09-30Fidelity Select Biotechnology0.4670.0911124283300
2024-08-31International Biotechnology Ord0.44791.2976119190041259252.9434
2024-09-30BNY Mellon Sm/Md Cp Gr I0.41730.31841110581-43065-3.7329
2024-08-31Fidelity Small Cap Growth K60.37450.1274996609101371.0276
2024-10-31BlackRock Health Sciences Opps Inv A0.33440.037288996200
Total 31.692712.625884341500+22480738+26.7%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets827,490
Total Liabilities350,525
Total Stockholder Equity476,965
 As reported
Total Liabilities 350,525
Total Stockholder Equity+ 476,965
Total Assets = 827,490

Assets

Total Assets827,490
Total Current Assets718,114
Long-term Assets109,376
Total Current Assets
Cash And Cash Equivalents 657,067
Net Receivables 993
Other Current Assets 60,054
Total Current Assets  (as reported)718,114
Total Current Assets  (calculated)718,114
+/-0
Long-term Assets
Property Plant Equipment 104,761
Long-term Assets Other 1,226
Long-term Assets  (as reported)109,376
Long-term Assets  (calculated)105,987
+/- 3,389

Liabilities & Shareholders' Equity

Total Current Liabilities52,474
Long-term Liabilities298,051
Total Stockholder Equity476,965
Total Current Liabilities
Short-term Debt 3,568
Accounts payable 1,418
Other Current Liabilities 47,488
Total Current Liabilities  (as reported)52,474
Total Current Liabilities  (calculated)52,474
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt48,661
Long-term Liabilities Other 248,943
Long-term Liabilities  (as reported)298,051
Long-term Liabilities  (calculated)297,604
+/- 447
Total Stockholder Equity
Common Stock12
Retained Earnings -1,071,618
Accumulated Other Comprehensive Income -898
Other Stockholders Equity 1,549,469
Total Stockholder Equity (as reported)476,965
Total Stockholder Equity (calculated)476,965
+/-0
Other
Capital Stock12
Cash and Short Term Investments 657,067
Common Stock Shares Outstanding 266,085
Liabilities and Stockholders Equity 827,490
Net Debt -604,838
Net Invested Capital 476,965
Net Working Capital 665,640
Property Plant and Equipment Gross 140,018
Short Long Term Debt Total 52,229



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302016-09-30
> Total Assets 
34,180
148,662
143,462
143,462
273,205
273,205
254,210
264,356
346,145
314,641
303,533
337,664
310,548
317,077
294,237
349,746
330,655
296,636
405,560
363,994
313,976
263,830
490,274
459,971
450,992
406,098
375,381
901,436
853,620
827,490
827,490853,620901,436375,381406,098450,992459,971490,274263,830313,976363,994405,560296,636330,655349,746294,237317,077310,548337,664303,533314,641346,145264,356254,210273,205273,205143,462143,462148,66234,180
   > Total Current Assets 
31,125
142,482
131,872
131,872
259,278
259,278
232,966
210,988
292,708
260,183
249,256
280,942
248,731
228,869
196,984
288,060
269,506
237,677
346,952
309,463
258,960
212,311
425,771
393,885
355,365
308,382
275,302
802,638
758,600
718,114
718,114758,600802,638275,302308,382355,365393,885425,771212,311258,960309,463346,952237,677269,506288,060196,984228,869248,731280,942249,256260,183292,708210,988232,966259,278259,278131,872131,872142,48231,125
       Cash And Cash Equivalents 
28,059
137,070
120,674
120,674
246,984
247,089
217,450
187,733
266,194
229,366
210,643
243,312
212,044
177,695
153,299
239,012
216,352
173,060
310,338
268,558
216,437
163,053
382,436
343,027
307,500
256,415
239,566
759,544
705,939
657,067
657,067705,939759,544239,566256,415307,500343,027382,436163,053216,437268,558310,338173,060216,352239,012153,299177,695212,044243,312210,643229,366266,194187,733217,450247,089246,984120,674120,674137,07028,059
       Net Receivables 
2,126
4,731
0
0
9,264
9,264
13,342
19,662
22,773
24,991
30,524
31,329
31,758
42,931
29,685
39,231
44,223
54,311
26,250
31,848
36,734
41,282
28,976
34,837
38,221
41,960
1,047
948
938
993
9939389481,04741,96038,22134,83728,97641,28236,73431,84826,25054,31144,22339,23129,68542,93131,75831,32930,52424,99122,77319,66213,3429,2649,264004,7312,126
       Other Current Assets 
688
681
0
11,198
822
12,189
2,174
3,593
3,741
5,826
279
334
247
988
14,000
9,817
237
545
240
83
150
135
203
13,696
37
127
34,689
12,074
51,723
60,054
60,05451,72312,07434,6891273713,696203135150832405452379,81714,0009882473342795,8263,7413,5932,17412,18982211,1980681688
   > Long-term Assets 
0
0
0
11,590
0
13,927
21,244
53,368
53,437
54,458
54,277
56,722
61,817
88,208
97,253
61,686
61,149
58,959
58,608
54,531
55,016
51,519
64,503
66,086
95,627
97,716
100,079
98,798
95,020
109,376
109,37695,02098,798100,07997,71695,62766,08664,50351,51955,01654,53158,60858,95961,14961,68697,25388,20861,81756,72254,27754,45853,43753,36821,24413,927011,590000
       Property Plant Equipment 
3,254
6,180
11,590
11,590
13,528
13,528
19,968
51,358
51,472
52,546
51,573
53,513
56,054
82,290
89,683
54,742
54,788
53,158
52,316
48,383
49,024
45,709
58,419
61,528
91,108
94,040
95,653
92,540
90,538
104,761
104,76190,53892,54095,65394,04091,10861,52858,41945,70949,02448,38352,31653,15854,78854,74289,68382,29056,05453,51351,57352,54651,47251,35819,96813,52813,52811,59011,5906,1803,254
       Intangible Assets 
9,499
7,295
0
0
399
399
0
0
0
0
254
214
186
172
158
135
0
0
65
0
25
8
0
0
0
0
0
0
0
0
00000000825065001351581721862142540000399399007,2959,499
       Other Assets 
0
0
0
0
0
399
1,276
2,010
1,965
1,912
2,450
2,995
5,577
5,746
7,412
6,809
6,249
5,714
6,227
6,102
5,967
5,802
6,084
0
4,519
3,676
0
0
0
0
00003,6764,51906,0845,8025,9676,1026,2275,7146,2496,8097,4125,7465,5772,9952,4501,9121,9652,0101,27639900000
> Total Liabilities 
3,493
6,061
16,363
16,363
17,740
17,740
21,568
46,473
47,923
45,000
48,694
50,186
51,596
80,266
84,205
50,179
46,973
51,906
92,240
92,851
99,455
102,676
191,600
193,051
221,656
225,580
263,907
319,406
325,776
350,525
350,525325,776319,406263,907225,580221,656193,051191,600102,67699,45592,85192,24051,90646,97350,17984,20580,26651,59650,18648,69445,00047,92346,47321,56817,74017,74016,36316,3636,0613,493
   > Total Current Liabilities 
2,735
5,033
15,501
15,501
17,139
17,139
21,076
19,784
22,305
20,563
24,984
26,051
27,267
30,810
33,634
30,599
28,187
34,563
28,551
28,840
35,517
38,818
46,366
39,637
41,063
37,540
44,737
43,985
40,904
52,474
52,47440,90443,98544,73737,54041,06339,63746,36638,81835,51728,84028,55134,56328,18730,59933,63430,81027,26726,05124,98420,56322,30519,78421,07617,13917,13915,50115,5015,0332,735
       Short-term Debt 
0
0
0
0
0
0
0
1,703
1,925
2,282
2,511
2,523
3,888
3,413
3,590
3,657
3,895
4,467
4,453
4,174
3,995
3,815
5,038
4,821
6,231
5,491
10,106
4,818
8,454
3,568
3,5688,4544,81810,1065,4916,2314,8215,0383,8153,9954,1744,4534,4673,8953,6573,5903,4133,8882,5232,5112,2821,9251,7030000000
       Short Long Term Debt 
0
0
0
0
0
0
0
1,703
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001,7030000000
       Accounts payable 
1,438
1,946
3,613
3,613
3,036
3,036
2,022
1,833
3,143
2,733
1,075
1,057
626
1,997
2,263
2,259
1,119
1,462
431
153
162
334
531
353
3,878
661
103
1,399
1,098
1,418
1,4181,0981,3991036613,8783535313341621534311,4621,1192,2592,2631,9976261,0571,0752,7333,1431,8332,0223,0363,0363,6133,6131,9461,438
       Other Current Liabilities 
1,297
3,087
0
11,888
1,845
14,103
19,054
1,170
1,343
493
716
955
247
402
496
574
678
312
150
24,513
31,360
34,669
40,797
34,463
259
483
34,528
37,768
31,352
47,488
47,48831,35237,76834,52848325934,46340,79734,66931,36024,5131503126785744964022479557164931,3431,17019,05414,1031,84511,88803,0871,297
   > Long-term Liabilities 
0
0
0
862
0
601
492
26,689
25,618
24,437
23,710
24,135
24,329
49,456
50,571
19,580
18,786
17,343
63,689
64,011
63,938
63,858
145,234
153,414
180,593
188,040
219,170
275,421
284,872
298,051
298,051284,872275,421219,170188,040180,593153,414145,23463,85863,93864,01163,68917,34318,78619,58050,57149,45624,32924,13523,71024,43725,61826,6894926010862000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
26,448
25,497
24,407
23,710
24,135
24,329
49,456
50,571
19,580
18,786
17,343
16,545
15,081
13,208
11,310
19,218
22,495
44,707
46,967
42,861
46,518
41,567
48,661
48,66141,56746,51842,86146,96744,70722,49519,21811,31013,20815,08116,54517,34318,78619,58050,57149,45624,32924,13523,71024,40725,49726,4480000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
26,448
0
0
0
0
0
0
0
0
0
0
47,016
48,806
50,615
52,443
125,900
130,805
135,764
140,778
170,899
228,494
238,663
248,943
248,943238,663228,494170,899140,778135,764130,805125,90052,44350,61548,80647,016000000000026,4480000000
> Total Stockholder Equity
30,687
142,601
127,098
127,099
255,465
255,465
232,642
217,883
298,222
269,641
254,839
287,478
258,952
236,811
210,032
299,567
283,682
244,730
313,320
271,143
214,521
161,154
298,674
266,920
229,336
180,518
111,474
582,030
527,844
476,965
476,965527,844582,030111,474180,518229,336266,920298,674161,154214,521271,143313,320244,730283,682299,567210,032236,811258,952287,478254,839269,641298,222217,883232,642255,465255,465127,099127,098142,60130,687
   Common Stock
1
1
0
0
2
2
2
2
2
2
2
3
3
3
3
3
3
3
4
4
4
4
8
8
8
8
8
130
12
12
1212130888884444333333322222220011
   Retained Earnings Total Equity000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
2,258
0
0
-15,488
-10,437
-19,309
-28,353
-8,691
-26,392
-28,211
-17,296
-5,861
-4,588
-3,046
-9,509
-8,570
-16,025
-33,510
-47,564
-38,898
-33,257
-27,957
-33,794
-28,992
-28,934
-27,908
-898
-898-27,908-28,934-28,992-33,794-27,957-33,257-38,898-47,564-33,510-16,025-8,570-9,509-3,046-4,588-5,861-17,296-28,211-26,392-8,691-28,353-19,309-10,437-15,488002,258000
   Capital Surplus 
0
0
0
0
0
0
0
368,680
486,369
494,080
500,560
580,772
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000580,772500,560494,080486,369368,6800000000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
2,784
-3,849
2,258
196,981
-9,802
348,118
361,429
368,798
486,487
494,198
500,678
580,890
586,228
590,487
595,134
716,662
732,408
733,910
843,226
845,566
848,488
851,942
1,007,743
1,010,159
1,012,827
1,015,695
1,019,020
1,542,086
1,545,264
1,549,469
1,549,4691,545,2641,542,0861,019,0201,015,6951,012,8271,010,1591,007,743851,942848,488845,566843,226733,910732,408716,662595,134590,487586,228580,890500,678494,198486,487368,798361,429348,118-9,802196,9812,258-3,8492,784



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,698
Cost of Revenue-6,565
Gross Profit-4,867-4,867
 
Operating Income (+$)
Gross Profit-4,867
Operating Expense-1,698
Operating Income-195,028-6,565
 
Operating Expense (+$)
Research Development149,981
Selling General Administrative45,648
Selling And Marketing Expenses1,097
Operating Expense1,698196,726
 
Net Interest Income (+$)
Interest Income11,921
Interest Expense-45,067
Other Finance Cost-26,671
Net Interest Income-6,475
 
Pretax Income (+$)
Operating Income-195,028
Net Interest Income-6,475
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-208,402-181,654
EBIT - interestExpense = -208,402
-208,402
-163,316
Interest Expense45,067
Earnings Before Interest and Taxes (EBIT)-163,335-163,335
Earnings Before Interest and Taxes (EBITDA)-156,770
 
After tax Income (+$)
Income Before Tax-208,402
Tax Provision--17,496
Net Income From Continuing Ops-158,163-190,906
Net Income-208,383
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses196,726
Total Other Income/Expenses Net-13,3746,475
 

Technical Analysis of Autolus
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Autolus. The general trend of Autolus is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Autolus's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Autolus Therapeutics Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.69 < 3.45 < 4.12.

The bearish price targets are: 2.56 > 2.21 > 2.15.

Tweet this
Autolus Therapeutics Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Autolus Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Autolus Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Autolus Therapeutics Ltd. The current macd is -0.21945959.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Autolus price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Autolus. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Autolus price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Autolus Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartAutolus Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Autolus Therapeutics Ltd. The current adx is 19.00.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Autolus shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Autolus Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Autolus Therapeutics Ltd. The current sar is 3.31213864.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Autolus Therapeutics Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Autolus Therapeutics Ltd. The current rsi is 28.98. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Autolus Therapeutics Ltd Daily Relative Strength Index (RSI) ChartAutolus Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Autolus Therapeutics Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Autolus price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Autolus Therapeutics Ltd Daily Stochastic Oscillator ChartAutolus Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Autolus Therapeutics Ltd. The current cci is -204.57490958.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Autolus Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartAutolus Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Autolus Therapeutics Ltd. The current cmo is -54.99816196.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Autolus Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartAutolus Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Autolus Therapeutics Ltd. The current willr is -96.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Autolus Therapeutics Ltd Daily Williams %R ChartAutolus Therapeutics Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Autolus Therapeutics Ltd.

Autolus Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Autolus Therapeutics Ltd. The current atr is 0.23596479.

Autolus Therapeutics Ltd Daily Average True Range (ATR) ChartAutolus Therapeutics Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Autolus Therapeutics Ltd. The current obv is -14,005,603.

Autolus Therapeutics Ltd Daily On-Balance Volume (OBV) ChartAutolus Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Autolus Therapeutics Ltd. The current mfi is 44.23.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Autolus Therapeutics Ltd Daily Money Flow Index (MFI) ChartAutolus Therapeutics Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Autolus Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-29MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-12-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Autolus Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Autolus Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.983
Ma 20Greater thanMa 502.977
Ma 50Greater thanMa 1003.589
Ma 100Greater thanMa 2003.776
OpenGreater thanClose2.700
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Autolus with someone you think should read this too:
  • Are you bullish or bearish on Autolus? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Autolus? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Autolus Therapeutics Ltd

I send you an email if I find something interesting about Autolus Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Autolus Therapeutics Ltd.

Receive notifications about Autolus Therapeutics Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.